Is XFOR or IBIO more profitable?

iBio has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -568.80%. iBio's return on equity of -40.66% beat X4 Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets X4 Pharmaceuticals -568.80% -63.05% -36.89% iBio N/A -40.66% -35.78%

Does the media favor XFOR or IBIO?

In the previous week, iBio had 1 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 3 mentions for iBio and 2 mentions for X4 Pharmaceuticals. iBio's average media sentiment score of 0.26 beat X4 Pharmaceuticals' score of 0.00 indicating that iBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment X4 Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral iBio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IBIO or LXEO more profitable?

iBio's return on equity of -40.66% beat Lexeo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets iBio N/A -40.66% -35.78% Lexeo Therapeutics N/A -41.85% -38.03%

Does the media refer more to IBIO or LXEO?

In the previous week, Lexeo Therapeutics had 3 more articles in the media than iBio. MarketBeat recorded 6 mentions for Lexeo Therapeutics and 3 mentions for iBio. Lexeo Therapeutics' average media sentiment score of 0.34 beat iBio's score of 0.26 indicating that Lexeo Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iBio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lexeo Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, IBIO or ABEO?

Abeona Therapeutics has higher revenue and earnings than iBio. Abeona Therapeutics is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iBio $100K 694.55 -$33.04M -$0.34 N/A Abeona Therapeutics $5.82M 49.96 $71.18M -$1.09 N/A

Is IBIO or ABEO more profitable?

iBio's return on equity of -40.66% beat Abeona Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets iBio N/A -40.66% -35.78% Abeona Therapeutics N/A -41.69% -30.36%

Does the media refer more to IBIO or ABEO?

In the previous week, Abeona Therapeutics had 12 more articles in the media than iBio. MarketBeat recorded 15 mentions for Abeona Therapeutics and 3 mentions for iBio. Abeona Therapeutics' average media sentiment score of 0.31 beat iBio's score of 0.26 indicating that Abeona Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iBio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Abeona Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, SABS or IBIO?

SAB Biotherapeutics has higher revenue and earnings than iBio. iBio is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SAB Biotherapeutics $1.32M 206.80 $13.27M -$1.30 N/A iBio $100K 694.55 -$33.04M -$0.34 N/A

Is SABS or IBIO more profitable?

SAB Biotherapeutics' return on equity of -6.74% beat iBio's return on equity. Company Net Margins Return on Equity Return on Assets SAB Biotherapeutics N/A -6.74% -6.06% iBio N/A -40.66% -35.78%

Does the media prefer SABS or IBIO?

In the previous week, SAB Biotherapeutics had 2 more articles in the media than iBio. MarketBeat recorded 5 mentions for SAB Biotherapeutics and 3 mentions for iBio. SAB Biotherapeutics' average media sentiment score of 0.27 beat iBio's score of 0.26 indicating that SAB Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SAB Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral iBio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate NLTX or IBIO?

iBio has a consensus target price of $5.29, suggesting a potential upside of 389.42%. Given iBio's stronger consensus rating and higher probable upside, analysts clearly believe iBio is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 iBio 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 3 Strong Buy rating(s) 3.11

Is NLTX or IBIO more profitable?

Neoleukin Therapeutics' return on equity of -37.22% beat iBio's return on equity. Company Net Margins Return on Equity Return on Assets Neoleukin Therapeutics N/A -37.22% -30.91% iBio N/A -40.66% -35.78%

iBio (IBIO) Competitors

$1.12 +0.02 (+1.35%)

Closing price 04:00 PM Eastern

Extended Trading

$1.12 0.00 (0.00%)

As of 04:28 PM Eastern

Compare

IBIO vs. XFOR, LXEO, ABEO, SABS, and NLTX

Should you buy iBio stock or one of its competitors? iBio's main competitors and comparable companies include X4 Pharmaceuticals (XFOR), Lexeo Therapeutics (LXEO), Abeona Therapeutics (ABEO), SAB Biotherapeutics (SABS), and Neoleukin Therapeutics (NLTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does iBio compare to X4 Pharmaceuticals?

X4 Pharmaceuticals (NASDAQ:XFOR) and iBio (NASDAQ:IBIO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

X4 Pharmaceuticals presently has a consensus target price of $11.25, suggesting a potential upside of 308.35%. iBio has a consensus target price of $5.29, suggesting a potential upside of 389.42%. Given iBio's stronger consensus rating and higher possible upside, analysts clearly believe iBio is more favorable than X4 Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
iBio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11

In the previous week, iBio had 1 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 3 mentions for iBio and 2 mentions for X4 Pharmaceuticals. iBio's average media sentiment score of 0.26 beat X4 Pharmaceuticals' score of 0.00 indicating that iBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
X4 Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
iBio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

iBio has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -568.80%. iBio's return on equity of -40.66% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-568.80%	-63.05%	-36.89%
iBio	N/A	-40.66%	-35.78%

X4 Pharmaceuticals has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market. Comparatively, iBio has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market.

iBio has lower revenue, but higher earnings than X4 Pharmaceuticals. iBio is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$35.11M	7.78	-$79.20M	-$1.20	N/A
iBio	$100K	694.55	-$33.04M	-$0.34	N/A

72.0% of X4 Pharmaceuticals shares are held by institutional investors. Comparatively, 7.9% of iBio shares are held by institutional investors. 1.1% of X4 Pharmaceuticals shares are held by company insiders. Comparatively, 1.6% of iBio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

iBio beats X4 Pharmaceuticals on 14 of the 17 factors compared between the two stocks.

How does iBio compare to Lexeo Therapeutics?

iBio (NASDAQ:IBIO) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

iBio has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market. Comparatively, Lexeo Therapeutics has a beta of 1.64, indicating that its share price is 64% more volatile than the broader market.

7.9% of iBio shares are held by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are held by institutional investors. 1.6% of iBio shares are held by company insiders. Comparatively, 2.0% of Lexeo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Lexeo Therapeutics had 3 more articles in the media than iBio. MarketBeat recorded 6 mentions for Lexeo Therapeutics and 3 mentions for iBio. Lexeo Therapeutics' average media sentiment score of 0.34 beat iBio's score of 0.26 indicating that Lexeo Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iBio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lexeo Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

iBio's return on equity of -40.66% beat Lexeo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-40.66%	-35.78%
Lexeo Therapeutics	N/A	-41.85%	-38.03%

iBio currently has a consensus price target of $5.29, suggesting a potential upside of 389.42%. Lexeo Therapeutics has a consensus price target of $18.13, suggesting a potential upside of 409.85%. Given Lexeo Therapeutics' higher possible upside, analysts plainly believe Lexeo Therapeutics is more favorable than iBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00

iBio has higher revenue and earnings than Lexeo Therapeutics. iBio is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$100K	694.55	-$33.04M	-$0.34	N/A
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.15	N/A

Summary

Lexeo Therapeutics beats iBio on 8 of the 15 factors compared between the two stocks.

How does iBio compare to Abeona Therapeutics?

iBio (NASDAQ:IBIO) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

iBio currently has a consensus price target of $5.29, suggesting a potential upside of 389.42%. Abeona Therapeutics has a consensus price target of $21.00, suggesting a potential upside of 312.98%. Given iBio's stronger consensus rating and higher possible upside, equities analysts clearly believe iBio is more favorable than Abeona Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

iBio has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market. Comparatively, Abeona Therapeutics has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market.

7.9% of iBio shares are held by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are held by institutional investors. 1.6% of iBio shares are held by insiders. Comparatively, 7.1% of Abeona Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Abeona Therapeutics had 12 more articles in the media than iBio. MarketBeat recorded 15 mentions for Abeona Therapeutics and 3 mentions for iBio. Abeona Therapeutics' average media sentiment score of 0.31 beat iBio's score of 0.26 indicating that Abeona Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iBio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Abeona Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Abeona Therapeutics has higher revenue and earnings than iBio. Abeona Therapeutics is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$100K	694.55	-$33.04M	-$0.34	N/A
Abeona Therapeutics	$5.82M	49.96	$71.18M	-$1.09	N/A

iBio's return on equity of -40.66% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-40.66%	-35.78%
Abeona Therapeutics	N/A	-41.69%	-30.36%

Summary

Abeona Therapeutics beats iBio on 8 of the 15 factors compared between the two stocks.

How does iBio compare to SAB Biotherapeutics?

SAB Biotherapeutics (NASDAQ:SABS) and iBio (NASDAQ:IBIO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

7.8% of SAB Biotherapeutics shares are held by institutional investors. Comparatively, 7.9% of iBio shares are held by institutional investors. 7.4% of SAB Biotherapeutics shares are held by insiders. Comparatively, 1.6% of iBio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

SAB Biotherapeutics presently has a consensus price target of $12.00, indicating a potential upside of 300.00%. iBio has a consensus price target of $5.29, indicating a potential upside of 389.42%. Given iBio's stronger consensus rating and higher probable upside, analysts clearly believe iBio is more favorable than SAB Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
iBio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11

In the previous week, SAB Biotherapeutics had 2 more articles in the media than iBio. MarketBeat recorded 5 mentions for SAB Biotherapeutics and 3 mentions for iBio. SAB Biotherapeutics' average media sentiment score of 0.27 beat iBio's score of 0.26 indicating that SAB Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SAB Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
iBio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

SAB Biotherapeutics has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market. Comparatively, iBio has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market.

SAB Biotherapeutics has higher revenue and earnings than iBio. iBio is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$1.32M	206.80	$13.27M	-$1.30	N/A
iBio	$100K	694.55	-$33.04M	-$0.34	N/A

SAB Biotherapeutics' return on equity of -6.74% beat iBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	-6.74%	-6.06%
iBio	N/A	-40.66%	-35.78%

Summary

SAB Biotherapeutics beats iBio on 9 of the 16 factors compared between the two stocks.

How does iBio compare to Neoleukin Therapeutics?

Neoleukin Therapeutics (NASDAQ:NLTX) and iBio (NASDAQ:IBIO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

In the previous week, iBio had 3 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 3 mentions for iBio and 0 mentions for Neoleukin Therapeutics. iBio's average media sentiment score of 0.26 beat Neoleukin Therapeutics' score of 0.00 indicating that iBio is being referred to more favorably in the news media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
iBio	Neutral

Neoleukin Therapeutics has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market. Comparatively, iBio has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market.

52.4% of Neoleukin Therapeutics shares are owned by institutional investors. Comparatively, 7.9% of iBio shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Comparatively, 1.6% of iBio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

iBio has higher revenue and earnings than Neoleukin Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
iBio	$100K	694.55	-$33.04M	-$0.34	N/A

Neoleukin Therapeutics' return on equity of -37.22% beat iBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
iBio	N/A	-40.66%	-35.78%

iBio has a consensus target price of $5.29, suggesting a potential upside of 389.42%. Given iBio's stronger consensus rating and higher probable upside, analysts clearly believe iBio is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
iBio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11

Summary

iBio beats Neoleukin Therapeutics on 11 of the 15 factors compared between the two stocks.

Get iBio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IBIO vs. The Competition

Export

Metric	iBio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$72.35M	$3.84B	$7.11B	$13.24B
Dividend Yield	N/A	3.64%	2.53%	15.88%
P/E Ratio	-3.31	13.44	274.42	26.03
Price / Sales	723.49	1,285.38	600.72	89.51
Price / Cash	N/A	121.76	77.38	51.25
Price / Book	0.73	16.64	10.92	6.32
Net Income	-$33.04M	-$22.67M	$3.50B	$361.43M
7 Day Performance	-5.46%	-2.99%	-2.07%	-1.66%
1 Month Performance	-14.12%	-10.68%	-6.32%	-3.93%
1 Year Performance	N/A	21.44%	8.92%	2.82%

iBio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IBIO iBio	2.8761 of 5 stars	$1.13 +1.4%	$5.29 +369.8%	N/A	$72.35M	$100K	N/A	23
XFOR X4 Pharmaceuticals	1.5594 of 5 stars	$3.11 -9.3%	$11.25 +261.7%	-21.8%	$340.07M	$35.11M	N/A	45	High Trading Volume
LXEO Lexeo Therapeutics	2.1391 of 5 stars	$3.52 -13.5%	$18.13 +414.9%	-45.5%	$333.93M	N/A	N/A	59	High Trading Volume
ABEO Abeona Therapeutics	2.9849 of 5 stars	$5.53 -5.0%	$21.00 +279.7%	-5.1%	$332.81M	$5.82M	N/A	226	Insider Trade
SABS SAB Biotherapeutics	2.9803 of 5 stars	$3.39 -3.1%	$12.00 +254.0%	+54.5%	$318.45M	$1.32M	N/A	86	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IBIO) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

iBio (IBIO) Competitors

IBIO vs. XFOR, LXEO, ABEO, SABS, and NLTX

How does iBio compare to X4 Pharmaceuticals?

Summary

How does iBio compare to Lexeo Therapeutics?

Summary

How does iBio compare to Abeona Therapeutics?

Summary

How does iBio compare to SAB Biotherapeutics?

Summary

How does iBio compare to Neoleukin Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO vs. The Competition

iBio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

iBio (IBIO) Competitors

IBIO vs. XFOR, LXEO, ABEO, SABS, and NLTX

How does iBio compare to X4 Pharmaceuticals?

Do analysts rate XFOR or IBIO?

Does the media favor XFOR or IBIO?

Is XFOR or IBIO more profitable?

Which has more volatility and risk, XFOR or IBIO?

Which has better valuation & earnings, XFOR or IBIO?

Do institutionals & insiders believe in XFOR or IBIO?

Summary

How does iBio compare to Lexeo Therapeutics?

Which has more volatility and risk, IBIO or LXEO?

Do insiders & institutionals believe in IBIO or LXEO?

Does the media refer more to IBIO or LXEO?

Is IBIO or LXEO more profitable?

Do analysts rate IBIO or LXEO?

Which has better earnings & valuation, IBIO or LXEO?

Summary

How does iBio compare to Abeona Therapeutics?

Do analysts recommend IBIO or ABEO?

Which has more risk and volatility, IBIO or ABEO?

Do insiders & institutionals have more ownership in IBIO or ABEO?

Does the media refer more to IBIO or ABEO?

Which has preferable valuation & earnings, IBIO or ABEO?

Is IBIO or ABEO more profitable?

Summary

How does iBio compare to SAB Biotherapeutics?

Do institutionals and insiders believe in SABS or IBIO?

Do analysts rate SABS or IBIO?

Does the media prefer SABS or IBIO?

Which has more risk & volatility, SABS or IBIO?

Which has better valuation and earnings, SABS or IBIO?

Is SABS or IBIO more profitable?

Summary

How does iBio compare to Neoleukin Therapeutics?

Does the media prefer NLTX or IBIO?

Which has more risk & volatility, NLTX or IBIO?

Do institutionals and insiders hold more shares of NLTX or IBIO?

Which has better earnings & valuation, NLTX or IBIO?

Is NLTX or IBIO more profitable?

Do analysts rate NLTX or IBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO vs. The Competition

iBio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools